MacroGenics FY2025 EPS Estimate Boosted by Leerink Partnrs

MacroGenics, Inc. (NASDAQ:MGNX) – Leerink Partnrs lifted their FY2025 earnings per share (EPS) estimates for MacroGenics in a research report issued on Wednesday, November 12th. Leerink Partnrs analyst J. Chang now expects that the biopharmaceutical company will post earnings per share of ($1.33) for the year, up from their prior forecast of ($2.29). The consensus estimate for MacroGenics’ current full-year earnings is ($1.06) per share. Leerink Partnrs also issued estimates for MacroGenics’ Q4 2025 earnings at ($0.37) EPS and FY2026 earnings at ($0.74) EPS.

MGNX has been the subject of a number of other research reports. Barclays assumed coverage on shares of MacroGenics in a research report on Wednesday, September 17th. They set an “overweight” rating and a $3.00 target price for the company. HC Wainwright reiterated a “neutral” rating and set a $2.00 price target on shares of MacroGenics in a research note on Monday, November 3rd. Leerink Partners cut their price target on shares of MacroGenics from $8.00 to $5.00 and set an “outperform” rating for the company in a research note on Friday, August 15th. Weiss Ratings restated a “sell (e+)” rating on shares of MacroGenics in a research report on Wednesday, October 8th. Finally, Wall Street Zen cut MacroGenics from a “hold” rating to a “sell” rating in a report on Saturday, August 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $3.60.

MacroGenics Price Performance

Shares of NASDAQ MGNX opened at $1.50 on Monday. The stock has a market capitalization of $94.81 million, a price-to-earnings ratio of -2.63 and a beta of 1.55. The firm’s 50 day simple moving average is $1.66 and its 200-day simple moving average is $1.59. MacroGenics has a 12 month low of $0.99 and a 12 month high of $3.84.

MacroGenics (NASDAQ:MGNX) last posted its quarterly earnings data on Wednesday, November 12th. The biopharmaceutical company reported $0.27 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.75. The company had revenue of $72.84 million for the quarter, compared to analyst estimates of $28.72 million. MacroGenics had a negative net margin of 21.99% and a negative return on equity of 40.24%.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in MGNX. SG Americas Securities LLC boosted its position in MacroGenics by 55.9% during the 3rd quarter. SG Americas Securities LLC now owns 17,179 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 6,161 shares in the last quarter. Quadrature Capital Ltd purchased a new stake in shares of MacroGenics during the second quarter worth about $26,000. State of Wyoming bought a new stake in MacroGenics during the 1st quarter valued at approximately $28,000. Engineers Gate Manager LP bought a new position in MacroGenics during the second quarter valued at $28,000. Finally, Walleye Capital LLC purchased a new stake in shares of MacroGenics in the second quarter valued at $30,000. 96.89% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at MacroGenics

In related news, Director William K. Heiden purchased 49,500 shares of the firm’s stock in a transaction on Wednesday, August 20th. The stock was purchased at an average cost of $1.49 per share, with a total value of $73,755.00. Following the completion of the purchase, the director owned 111,000 shares in the company, valued at approximately $165,390. This trade represents a 80.49% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 13.00% of the stock is owned by company insiders.

About MacroGenics

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.